PMID- 30036884
OWN - NLM
STAT- MEDLINE
DCOM- 20180731
LR  - 20181114
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Print)
IS  - 0030-2414 (Linking)
VI  - 94 Suppl 1
IP  - Suppl 1
DP  - 2018
TI  - Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.
PG  - 19-28
LID - 10.1159/000489065 [doi]
AB  - OBJECTIVES: Predictive factors of response to eribulin are lacking. We aimed to 
      investigate the activity and safety of eribulin in a real-world population of 
      metastatic breast cancer (MBC) patients and to identify possible predictive 
      factors of progression-free survival (PFS) and objective response. METHODS: We 
      retrospectively analyzed 71 eribulin-treated MBC patients. Best response rate, 
      PFS, and adverse events (AEs) were evaluated. The impact of different 
      clinical-pathological factors on PFS was evaluated using the Cox proportional 
      hazards model. Predictive factors of response were identified by discriminant 
      function analysis (DFA). RESULTS: Median PFS was 3.75 months (95% CI, 2.39-4.48); 
      12 patients (16.90%) achieved partial response (PR), 27 (38.03%) stable disease. 
      The most common AEs were fatigue (25.83%), neutropenia (16.56%), and peripheral 
      neuropathy (13.91%). A worse performance status (p = 0.025) and a higher number 
      of metastatic organ sites (p = 0.011) were associated with a worse PFS under 
      eribulin. Overall, in the DFA-predictive model, neutrophil-to-lymphocyte ratio at 
      baseline, estrogen receptor, Ki67, histology, and age were predictive of PR with 
      100% accuracy. CONCLUSIONS: Activity and safety profiles of eribulin were 
      consistent with literature data. Performance status and number of metastatic 
      sites were predictive factors of PFS. DFA could be a promising tool to 
      discriminate responses to eribulin among MBC patients.
CI  - (c) 2018 S. Karger AG, Basel.
FAU - De Sanctis, Rita
AU  - De Sanctis R
AD  - Department of Medical Oncology and Hematology, Humanitas Cancer Center and 
      Research Hospital, IRCCS, Rozzano, Milan, Italy.
AD  - Molecular and Cellular Networks Lab, Department of Anatomy, Histology, Forensic 
      Medicine and Orthopaedics, "Sapienza" University, Rome, Italy.
FAU - Agostinetto, Elisa
AU  - Agostinetto E
AD  - Department of Medical Oncology and Hematology, Humanitas Cancer Center and 
      Research Hospital, IRCCS, Rozzano, Milan, Italy.
FAU - Masci, Giovanna
AU  - Masci G
AD  - Department of Medical Oncology and Hematology, Humanitas Cancer Center and 
      Research Hospital, IRCCS, Rozzano, Milan, Italy.
FAU - Ferraro, Emanuela
AU  - Ferraro E
AD  - Department of Medical Oncology and Hematology, Humanitas Cancer Center and 
      Research Hospital, IRCCS, Rozzano, Milan, Italy.
FAU - Losurdo, Agnese
AU  - Losurdo A
AD  - Department of Medical Oncology and Hematology, Humanitas Cancer Center and 
      Research Hospital, IRCCS, Rozzano, Milan, Italy.
FAU - Vigano, Alessandro
AU  - Vigano A
AD  - Molecular and Cellular Networks Lab, Department of Anatomy, Histology, Forensic 
      Medicine and Orthopaedics, "Sapienza" University, Rome, Italy.
FAU - Antunovic, Lidija
AU  - Antunovic L
AD  - Department of Nuclear Medicine, Humanitas Cancer Center and Research Hospital, 
      IRCCS, Rozzano, Milan, Italy.
FAU - Zuradelli, Monica
AU  - Zuradelli M
AD  - Department of Medical Oncology and Hematology, Humanitas Cancer Center and 
      Research Hospital, IRCCS, Rozzano, Milan, Italy.
FAU - Torrisi, Rosalba Maria Concetta
AU  - Torrisi RMC
AD  - Department of Medical Oncology and Hematology, Humanitas Cancer Center and 
      Research Hospital, IRCCS, Rozzano, Milan, Italy.
FAU - Santoro, Armando
AU  - Santoro A
AD  - Department of Medical Oncology and Hematology, Humanitas Cancer Center and 
      Research Hospital, IRCCS, Rozzano, Milan, Italy.
AD  - Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20180723
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Furans)
RN  - 0 (Ketones)
RN  - LR24G6354G (eribulin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Breast Neoplasms/*drug therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Furans/*therapeutic use
MH  - Humans
MH  - Ketones/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC6193748
OTO - NOTNLM
OT  - Discriminant functional analysis
OT  - Eribulin
OT  - Metastatic breast cancer
OT  - Progression-free survival
EDAT- 2018/07/24 06:00
MHDA- 2018/08/01 06:00
PMCR- 2018/07/23
CRDT- 2018/07/24 06:00
PHST- 2018/07/24 06:00 [pubmed]
PHST- 2018/08/01 06:00 [medline]
PHST- 2018/07/24 06:00 [entrez]
PHST- 2018/07/23 00:00 [pmc-release]
AID - 000489065 [pii]
AID - ocl-0094-0019 [pii]
AID - 10.1159/000489065 [doi]
PST - ppublish
SO  - Oncology. 2018;94 Suppl 1(Suppl 1):19-28. doi: 10.1159/000489065. Epub 2018 Jul 
      23.